NICE recommends guselkumab for ulcerative colitis and Crohn’s disease

Patients with moderately to severely active ulcerative colitis or Crohn’s disease will now be able to access guselkumab (Tremfya; Janssen Biotech) on the NHS, when other treatments have not worked. Final guidance published by the National Institute for Health and Care Excellence (NICE) on 28 August 2025 has recommended that guselkumab can be used as an […]

Publication Details

Journal: Pharmaceutical journal/The pharmaceutical journal
Published: 2025-01-01
DOI: https://doi.org/10.1211/pj.2025.1.371925
Primary Topic: Eosinophilic Esophagitis
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

NICE recommends guselkumab for ulcerative colitis and Crohn’s disease

Jan 1, 2025

Pharmaceutical journal/The pharmaceutical journal

Eosinophilic Esophagitis

article

NICE recommends guselkumab for ulcerative colitis and Crohn’s disease

January 1, 2025article en

Abstract

Pharmaceutical journal/The pharmaceutical journal

Openalex Percentile: Top 62%

Eosinophilic Esophagitis

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NICE recommends guselkumab for ulcerative colitis and Crohn’s disease · Pharmaceutical journal/The pharmaceutical journal (2025) | TGRS Research Map | TGRS